| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 25.3 | 31.1 |
| Gross profit | 6.8 | 7.8 |
| Profit before tax | -40.0 | -9.7 |
| Net income | -40.1 | -10.0 |
| EPS (diluted, $ a share) | $-1.08 | $-0.29 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -18.6% |
|---|---|
| Gross margin | 27.0% |
| Operating margin | -3.5% |
10-Q filed with the SEC, NASDAQ: LFCR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Lifecore Biomedical, Inc. \De\: key numbers
- Share price
- $6.41Close, Nov 16
- Market cap
- $243M
- Shares outstanding
- 37.91MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Lifecore Biomedical, Inc. \De\
All →Lifecore Biomedical, Inc. \De\ M&A Deal with Lifecore Inc.
Lifecore Biomedical announced that the Department of Justice and the Federal Trade Commission granted early termination of the HSR Act waiting period for its pending merger with Lifecore Inc. This satisfies a key regulatory closing condition for the transaction, which remains subject to stockholder approval and other customary conditions. Lifecore Biomedical will become a wholly owned subsidiary of Lifecore Inc. upon completion of the deal.
- Counterparty
- Lifecore Inc.
Lifecore Biomedical, Inc. \De\ Financial Results
Lifecore Biomedical reported Q3 2026 financial results, showing a revenue decrease of 18.6% to $25.3 million compared to the prior year. The company reported a net loss of $40.1 million, or $1.08 per diluted share, while highlighting several new business wins in its CDMO pipeline including technology transfer projects and development-phase programs.
- Term
- Q3 2026
“During the third quarter, Lifecore secured two new technology transfer projects. One will support process performance qualification (PPQ) batches for a biotech company’s new drug application (NDA) for a new chemical entity, and the other will support a currently marketed product for a large pharmaceutical company. We believe these programs will add to Lifecore’s high-value pipeline, and we expect each to contribute to the company’s long-term revenue growth objectives, beginning in 2027”
Paul Josephs, president and chief executive officer of Lifecore
Lifecore Biomedical, Inc. \De\ M&A Deal with Lifecore Inc.
Lifecore Biomedical established November 4, 2026, as the record date for a special meeting of stockholders to vote on its previously announced merger agreement with Lifecore Inc. and Hazel Merger Sub, Inc. The company will file a proxy statement to solicit shareholder approval for the adoption of the merger agreement.
- Counterparty
- Lifecore Inc.
Lifecore Biomedical, Inc. \De\ Wins Contract from Alcon Research, LLC
Lifecore Biomedical extended its contract manufacturing agreement with Alcon Research, LLC, pushing the expiration date from 2031 to December 31, 2034. The amendment establishes Alcon's minimum purchase obligations through the new term and includes a non-compete provision regarding certain products starting in November 2026.
- Counterparty
- Alcon Research, LLC
- Term
- through Dec 2034
Lifecore Biomedical, Inc. \De\ Signs $664M M&A Deal with Webster Equity Partners
Lifecore Biomedical has entered into a definitive agreement to be acquired by Webster Equity Partners for up to $663.7 million. Common stockholders will receive $6.28 per share in cash at closing plus contingent value rights (CVRs) worth up to an additional $160 million in aggregate based on performance milestones. The transaction represents a 49.5% premium to the company's last closing price and will result in Lifecore becoming a privately held company.
- Value
- $664M
- Counterparty
- Webster Equity Partners